ArticleBritish journal of cancer2016
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Identification of common genetic variants inJournal of biomedical research · 2024Article
- Article
- Regularized survival learning and cross-database analysis enabled identification of colorectal cancer prognosis-related immune genes.Frontiers in genetics · 2023Article
- Low KCNQ1 expression is associated with unfavorable outcome and metabolism of gastric cancer.American journal of translational research · 2023Article
- Review
- KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer.BMC cancer · 2022Article
- A Novel Role of Arrhythmia-Related GeneInternational journal of molecular sciences · 2022Article
- KCNQ Potassium Channels as Targets of Botanical Folk Medicines.Annual review of pharmacology and toxicology · 2022Review
- Article
- A fast score test for generalized mixture models.Biometrics · 2020Article
- Fasting Serum Levels of Potassium and Sodium in Relation to Long-Term Risk of Cancer in Healthy Men.Clinical epidemiology · 2020Article
- Interplay Between Ion Channels and the Wnt/β-Catenin Signaling Pathway in Cancers.Frontiers in pharmacology · 2020Review
- Sexual Dimorphism in Colon Cancer.Frontiers in oncology · 2020Review
- Role of ion channels in gastrointestinal cancer.World journal of gastroenterology · 2019Review
- Knockdown of KCNQ1OT1 Suppresses Cell Invasion and Sensitizes Osteosarcoma Cells to CDDP by Upregulating DNMT1-Mediated Kcnq1 Expression.Molecular therapy. Nucleic acids · 2019Article
- Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort study.BMC gastroenterology · 2019Article
- Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adults.Biomarker research · 2019Article
- The Identification of Differentially Expressed Genes Showing Aberrant Methylation Patterns in Pheochromocytoma by Integrated Bioinformatics Analysis.Frontiers in genetics · 2019Article
- An integrated prediction model of recurrence in endometrial endometrioid cancers.Cancer management and research · 2019Article
- A 65‑gene signature for prognostic prediction in colon adenocarcinoma.International journal of molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most common cancer worldwide. Accurately identifying stage II CRC patients at risk for recurrence is an unmet clinical need. KCNQ1 was previously identified as a tumour suppressor gene and loss of expression was associated with poor survival in patients with CRC liver metastases. In this study the prognostic value of KCNQ1 in stage II and stage III colon cancer patients was examined.
methodsKCNQ1 mRNA expression was assessed in 90 stage II colon cancer patients (AMC-AJCCII-90) using microarray gene expression data. Subsequently, KCNQ1 protein expression was evaluated in an independent cohort of 386 stage II and stage III colon cancer patients by immunohistochemistry of tissue microarrays.
resultsLow KCNQ1 mRNA expression in stage II microsatellite stable (MSS) colon cancers was associated with poor disease-free survival (DFS) (P=0.025). Loss of KCNQ1 protein expression from epithelial cells was strongly associated with poor DFS in stage II MSS (P<0.0001), stage III MSS (P=0.0001) and stage III microsatellite instable colon cancers (P=0.041). KCNQ1 seemed an independent prognostic value in addition to other high-risk parameters like angio-invasion, nodal stage and microsatellite instability-status.
conclusionsWe conclude that KCNQ1 is a promising biomarker for prediction of disease recurrence and may aid stratification of patients with stage II MSS colon cancer for adjuvant chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.